THE EFFECT OF THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ZOFENOPRIL ON MORTALITY AND MORBIDITY AFTER ANTERIOR MYOCARDIAL-INFARCTION

被引:639
作者
AMBROSIONI, E
BORGHI, C
MAGNANI, B
机构
[1] UNIV BOLOGNA, DEPT INTERNAL MED, BOLOGNA, ITALY
[2] UNIV BOLOGNA, DEPT CARDIOL, BOLOGNA, ITALY
关键词
D O I
10.1056/NEJM199501123320203
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Left ventricular dilatation and neuroendocririe activation are common after acute anterior myocardial infarction. Long-term treatment with an angiotensin-converting-enzyme (ACE) inhibitor may improve outcome by attenuating these processes. We investigated whether the ACE inhibitor zofenopril, administered for six weeks after anterior myocardial infarction, could improve both short-term and long-term outcome. Methods. A total of 1556 patients were enrolled within 24 hours after the onset of symptoms of acute anterior myocardial infarction, and they were randomly assigned in a double-blind fashion to receive either placebo (784 patients) or zofenopril (772 patients) for six weeks. At this time we assessed the incidence of death or severe congestive heart failure. The patients were reexamined after one year to assess survival. Results. The incidence of death or severe congestive heart failure at six weeks was significantly reduced in the zofenopril group (55 patients, 7.1 percent), as compared with the placebo group (83 patients, 10.6 percent); the cumulative reduction in the risk of death or severe congestive heart failure was 34 percent (95 percent confidence interval, 8 to 54 percent; P = 0.018). The reduction in risk was 46 percent (95 percent confidence interval, 11 to 71 percent; P = 0.018) for severe congestive heart failure and 25 percent (95 percent confidence interval, -11 to 60 percent; P = 0.19) for death. After one year of observation, the mortality rate was significantly lower in the zofenopril group (10.0 percent) than in the placebo group (14.1 percent); the reduction in risk was 29 percent (95 percent confidence interval, 6 to 51 percent; P = 0.017). Conclusions. Treatment with zofenopril significantly improved both short-term and long-term outcome when this drug was started within 24 hours after the onset of acute anterior myocardial infarction and continued for six weeks.
引用
收藏
页码:80 / 85
页数:6
相关论文
共 34 条
  • [1] AMBROSIONI E, 1991, AM J CARDIOL, V68, pD101
  • [2] Ambrosioni Ettore, 1994, Controlled Clinical Trials, V15, P201, DOI 10.1016/0197-2456(94)90057-4
  • [3] [Anonymous], 1988, LANCET, V2, P349
  • [4] [Anonymous], 1986, LANCET, V1, P397
  • [5] [Anonymous], 1986, LANCET, V2, P57
  • [6] BALL SG, 1993, LANCET, V342, P821
  • [7] EARLY AND LATE ANGIOTENSIN-CONVERTING ENZYME-INHIBITION IN ACUTE MYOCARDIAL-INFARCTION
    BORGHI, C
    BACCHELLI, S
    ESPOSTI, DD
    AMBROSIONI, E
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1993, 72 (19) : G169 - G174
  • [8] CORONARY THROMBOLYSIS
    CAIRNS, JA
    COLLINS, R
    FUSTER, V
    PASSAMANI, ER
    [J]. CHEST, 1989, 95 (02) : S73 - S87
  • [9] DIFFERENTIATION OF ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS BY THEIR SELECTIVE-INHIBITION OF ACE IN PHYSIOLOGICALLY IMPORTANT TARGET ORGANS
    CUSHMAN, DW
    WANG, FL
    FUNG, WC
    HARVEY, CM
    DEFORREST, JM
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 1989, 2 (04) : 294 - 306
  • [10] PRECLINICAL PHARMACOLOGY OF ZOFENOPRIL, AN INHIBITOR OF ANGIOTENSIN-I CONVERTING ENZYME
    DEFORREST, JM
    WALDRON, TL
    KRAPCHO, J
    TURK, C
    RUBIN, B
    POWELL, JR
    CUSHMAN, DW
    PETRILLO, EW
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1989, 13 (06) : 887 - 894